-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...

-The Hindu   The absence of a comprehensive rehabilitation policy for surrendered militants has made life hellish for those who decided to give themselves up and join the mainstream Jammu & Kashmir's first "Surrender Policy" was floated by Governor Gen. (retd.) K.V. Krishna Rao's administration in 1995. It was almost identical to the policies introduced for militants involved in the North East and Naxalite insurgencies: Rs.1.5 lakh worth of fixed deposit receipts payable...

-The Economic Times In what could hobble the government's plans to give Aadhar a key role in banking and a central pin of the direct cash transfer scheme, several state-run banks have refused to bear any liability for transactions done with customers that were authenticated through the unique identity (UID) mechanism. Banks and the Reserve Bank of India (RBI) had been convinced by the finance ministry to use Aadhar to fulfill the...

-Live Mint CERC calls for a variable ‘compensatory tariff' to be offered to Adani Power till fuel situation stabilizes In an unprecedented move, India's apex power sector regulator offered a bailout package to Adani Power Ltd in a late Tuesday order to offset losses on account of the unexpected increase in the prices of imported coal and the unavailability of domestic coal for the company's 4,620 megawatts (MW) thermal power project at...

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...